The Journal of Organic Chemistry
Page 6 of 9
(E)-3-(3-(anthracen-9-yl)acryloyl)oxazolidin-2-one (18):
3-(4-Methoxybenzoyl)oxazolidin-2-one (24):
Was synthesized according to the general procedure 1 with 3-(9-an-
thryl)acrolein (116 mg, 0.499 mmol, 1 eq.). The product was obtained
as yellow solid (137.9 mg, 0.435 mmol, 87%), mp: 194–196 °C. H
NMR (400 MHz, CDCl3) δ 8.84 (d, J = 16.0 Hz, 1H), 8.48 (s, 1H),
8.38–8.27 (m, 2H), 8.04–7.98 (m, 2H), 7.85 (d, J = 16.0 Hz, 1H), 7.55–
7.45 (m, 4H), 4.54 (t, J = 8.0 Hz, 2H), 4.24 (t, J = 8.0 Hz, 2H). 13C
NMR (101 MHz, CDCl3) δ 165.2, 153.7, 143.2, 131.3, 129.7, 129.4,
129.0, 128.8, 126.6, 125.7, 125.5, 125.3, 62.4, 43.0. HRMS (ESI/Q-
TOF) m/z [M+H]+ calcd for C20H16NO3 318.1130; found 318.1129.
FTIR-ATR (νmax/cm−1): 1764 (vs) (CO), 1684 (s) (CO).
Was synthesized according to the general procedure 2 with 4-methox-
ybenzaldehyde (69.7 mg, 0.512 mmol, 1 eq.). The product was obtained
as white solid (72.7 mg, 0.329 mmol, 64%). The NMR matches re-
ported values.76 1H NMR (400 MHz, CDCl3) δ 7.73–7.66 (m, 2H),
6.9–6.88 (m, 2H), 4.48 (t, J = 7.9 Hz, 2H), 4.15 (t, J = 7.9 Hz, 2H), 3.86
(s, 3H). 13C NMR (101 MHz, CDCl3) δ 169.2, 163.4, 153.7, 132.0,
124.6, 113.4, 62.4, 55.6, 44.1.
1
2
3
4
5
6
7
8
1
3-(Cyclohexanecarbonyl)oxazolidin-2-one (25): Was synthesized ac-
cording to a modified general procedure 2, with cyclohexanecarboxal-
dehyde (56.1 mg, 0.500 mmol, 1.0 eq.), 2-mesityl-6,7-dihydro-5H-pyr-
rolo[2,1-c][1,2,4]triazol-2-ium chloride (cat 4) (6.7 mg, 0.025 mmol,
0.05 eq) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (60 µl, 0.40
mmol, 0.8 eq.). The product was obtained as a faintly yellow oil (63.2
mg, 0.320 mmol, 64%).1H NMR (400 MHz, CDCl3) δ 4.39 (t, J = 8.2
Hz, 2H), 4.00 (t, J = 8.2 Hz, 2H), 3.54–3.46 (m, 1H), 1.91–1.85 (m,
2H), 1.81–1.75 (m, 2H), 1.72–1.66 (m, 1H), 1.47–1.33 (m, 4H), 1.29–
1,21 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 176.9, 153.3, 62.0, 42.9,
42.0, 29.2, 25.9, 25.6. HRMS (ESI/Q-TOF) m/z [M+H]+ calcd for
C10H16NO3 198.1130; found: 198.1125 . FTIR-ATR (νmax/cm−1): 1771
(vs)(CO), 1692 (vs) (CO).
9
3-((2E,4E)-hexa-2,4-dienoyl)oxazolidin-2-one (19):
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Was synthesized according to the general procedure 2 with sorbic al-
dehyde (58.1 µl, 0.500 mmol, 1 eq.) and catalyst 4 (0.02 eq.). The prod-
uct was obtained as a white solid (63.5 mg, 0.351 mmol, 70%). The
NMR matches reported values.75 1H NMR (400 MHz, CDCl3) δ 7.45
(dd, J = 15.2, 10.5 Hz, 1H), 7.20 (d, J = 15.1 Hz, 1H), 6.37–6.17 (m,
1H), 4.46–4.38 (m, 2H), 4.12–4.04 (m, 2H), 1.88 (d, J = 6.2 Hz, 3H).
13C NMR (101 MHz, CDCl3) δ 165.9, 153.7, 146.9, 141.4, 130.5,
117.6, 62.1, 42.9, 19.0.
3-(benzo[d][1,3]dioxole-5-carbonyl)oxazolidin-2-one (20):
Was synthesized according to the general procedure 2 with piperonal
(75.1 mg, 0.500 mmol, 1 eq.). The product was obtained as white solid
(74.1 mg, 0.315 mmol, 63%), mp: 150–153 °C. 1H NMR (400 MHz,
CDCl3) δ 7.31–7.29 (m, 1H), 7.16–7.14 (m, 1H), 6.85–6.83 (m, 1H),
6.04 (s, 2H), 4.48 (t, J = 7.8 Hz, 2H), 4.14 (t, J = 7.8 Hz, 2H). 13C NMR
(101 MHz, CDCl3) δ 168.9, 153.6, 151.6, 147.4, 126.2, 125.6, 109.8,
107.8, 102.0, 62.4, 44.1. HRMS (ESI/Q-TOF) m/z [M+H]+ calcd for
C11H9NO5 236.0559; found 236.0558. FTIR-ATR (νmax/cm−1): 1794
(s) (CO), 1671 (vs) (CO).
(R)-3-cinnamoyl-4-phenyloxazolidin-2-one (26):
Was synthesized according to the general procedure 3 with (R)-(−)-4-
phenyl-2-oxazolidinone (82.4 mg, 0.505 mmol, 1 eq.). The product was
obtained as a yellow solid (107.9 mg, 0.368 mmol, 73%).The NMR
matches reported values.77 1H NMR (400 MHz, CDCl3) δ 7.94 (d, J =
15.8 Hz, 1H), 7.79 (d, J = 15.7 Hz, 1H), 7.63–7.55 (m, 2H), 7.44–7.30
(m, 8H), 5.56 (dd, J = 8.7, 3.9 Hz, 1H), 4.75 (t, J = 8.8 Hz, 1H), 4.33
(dd, J = 8.9, 3.9 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 164.8, 153.8,
146.7, 139.0, 134.5, 130.7, 129.2, 128.9, 128.7, 128.6, 126.0, 116.8,
70.0, 57.9. [α]ꢁꢀꢂ = −5.8 (c 0.01, CHCl3)
3-(2-methoxybenzoyl)oxazolidin-2-one (21):
Was synthesized according to the general procedure 2 with 2-methox-
ybenzaldehyde (68.1 mg, 0.500 mmol, 1 eq.). The product was obtained
as light yellow solid (87.9 mg, 0.397 mmol, 79%). The NMR matches
reported values.76 1H NMR (400 MHz, CDCl3) δ 7.47–7.40 (m, 1H),
7.35–7.30 (m, 1H), 7.04–6.98 (m, 1H), 6.94–6.89 (m, 1H), 4.44–4.36
(m, 2H), 4.18–4.11 (m, 2H), 3.81 (s, 3H). 13C NMR (101 MHz,
CDCl3) δ 167.8, 156.9, 152.5, 132.3, 128.7, 123.8, 120.5, 110.9, 62.1,
55.8, 42.9.
(R)-3-cinnamoyl-4-isopropyloxazolidin-2-one (27):
Was synthesized according to the general procedure 3 with (R)-(+)-4-
isopropyl-2-oxazolidinone (67.3 mg, 0.511 mmol, 1 eq.). The product
was obtained as a yellow oil (66.8 mg, 0.258 mmol, 50%). The NMR
matches reported values.23 1H NMR (400 MHz, CDCl3) δ 7.93 (d, J =
15.7 Hz, 1H), 7.85 (d, J = 15.7 Hz, 1H), 7.65–7.59 (m, 2H), 7.43–7.36
(m, 3H), 4.60–4.52 (m, 1H), 4.35–4.22 (m, 2H), 2.52–2.40 (m, 1H),
0.96 (d, J = 7.0 Hz, 3H), 0.92 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz,
CDCl3) δ 165.3, 154.3, 146.3, 134.7, 130.7, 129.0, 128.7, 117.2, 63.5,
58.8, 28.6, 18.2, 14.8. [α]ꢁꢀꢂ = −89.2 (c 0.01, CHCl3)
3-(2-Chlorobenzoyl)oxazolidin-2-one (22):
Was synthesized according to the general procedure 2 with 2-chloro-
benzaldehyde (70.4 mg, 0.500 mmol, 1 eq.). The product was obtained
as faintly yellow solid (48.0 mg, 0.213 mmol, 43%), mp: 97–98 °C.
1H NMR (400 MHz, CDCl3) δ 7.44–7.38 (m, 2H), 7.36–7.30 (m, 2H),
4.51(t, J = 7.9 Hz, 2H), 4.22 (t, J = 7.79 Hz, 2H) 13C NMR (101 MHz,
CDCl3) δ 167.0, 152.3, 134.1, 131.5, 130.8, 129.5, 128.2, 126.9, 62.4,
42.6. HRMS (ESI/Q-TOF) m/z [M+H]+ calcd for C10H9ClNO3
226.0271; found 226.0273. FTIR-ATR (νmax/cm−1): 1775 (vs) (CO),
1686 (vs) (CO).
(R)-4-benzyl-3-cinnamoyloxazolidin-2-one (28):
Was synthesized according to the general procedure 3 with (R)-(+)-4-
benzyl-2-oxazolidinone (81.7 mg, 0.461 mmol, 1 eq.). The product was
obtained as off-white solid (91.9 mg, 0.299 mmol, 65%). The NMR
matches reported values.23 1H NMR (400 MHz, CDCl3) δ 7.93 (d, J =
1.5 Hz, 2H), 7.67–7.62 (m, 2H), 7.44–7.39 (m, 3H), 7.38–7.32 (m, 2H),
7.31–7.27 (m, 1H), 7.26–7.22 (m, 2H), 4.85–4.76 (m, 1H), 4.29–4.19
(m, 2H), 3.38 (dd, J = 13.4, 3.3 Hz, 1H), 2.86 (dd, J = 13.4, 9.5 Hz,
1H). 13C NMR (101 MHz, CDCl3) δ 165.3, 153.7, 146.6, 135.5, 134.7,
130.9, 129.6, 129.1, 129.1, 128.8, 127.5, 117.1, 66.3, 55.6, 38.1. [α]ꢀꢁꢂ
= −63.3 (c 0.01, CHCl3).
3-(3,4-Methylbenzoyl)oxazolidin-2-one (23):
Was synthesized according to the general procedure 2 with 3,4-dime-
thylbenzaldehyde (67.1 mg, 0.500 mmol, 1 eq.). The product was ob-
tained as faintly yellow solid (65.5 mg, 0.300 mmol, 60%), mp: 143–
(S)-3-cinnamoyl-4-isobutyloxazolidin-2-one (29):
1
145 °C. H NMR (400 MHz, CDCl3) δ 7.45 (s, 1H), 7.43–7.39 (m,
Was synthesized according to the general procedure 3 with (S)-(+)-4-
isobutyl-2-oxazolidinone (63.1 mg, 0.441 mmol, 1 eq.). The product
was obtained as a yellow oil (62.7 mg, 0.229 mmol, 52%). The NMR
matches reported values.78 1H NMR (400 MHz, CDCl3) δ 7.90 (d, J =
15.7 Hz, 1H), 7.83 (d, J = 15.8 Hz, 1H), 7.65–7.56 (m, 2H), 7.43–7.34
(m, 3H), 4.65–4.56 (m, 1H), 4.42 (ddd, J = 8.7, 7.8, 0.9 Hz, 1H), 4.14
(dd, J = 8.7, 2.9 Hz, 1H), 1.91–1.82 (m, 1H), 1.70–1.60 (m, 1H), 1.58–
1.48 (m, 1H), 1.02–0.95 (m, 6H). 13C NMR (101 MHz, CDCl3) δ
165.2, 153.8, 146.2, 134.7, 130.7, 129.0, 128.7, 117.2, 67.8, 53.4, 41.7,
25.0, 23.6, 21.8. [α]ꢁꢀꢂ = +88.0 (c 0.01, CHCl3).
1H), 7.20–7.16 (m, 1H), 4.49 (t, J = 7.8 Hz, 2H), 4.16 (t, J = 7.7 Hz,
2H), 2.31 (s, 3H), 2.29 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.0,
153.5, 142.1, 136.5, 130.4, 130.1, 129.2, 127.0, 62.3, 44.0, 20.2, 19.8.
HRMS (ESI/Q-TOF) m/z [M+H]+ calcd for C12H13NO3 220.0974;
found 220.0974. FTIR-ATR (νmax/cm−1): 1758 (vs) (CO), 1671 (vs)
(CO).
ACS Paragon Plus Environment